Capella

We have launched our fourth program as part of our Alnylam 5x15 product development strategy.  ALN-APC is an RNAi therapeutic for the treatment of hemophilia, and as with our other Alnylam 5x15 programs, targets protein C, a genetically defined target, and will utilize Alnylam’s existing delivery platform. [spotlight-link icon="release" href="http://investors.alnylam.com/releasedetail.cfm?ReleaseID=734372" type=" "]Read our press release[/spotlight-link] [spotlight-link icon="podcast" href="http://www.alnylam.com/web/assets/alnylam_podcast_ALN-APCprogram.mp3" type="(13.3MB mp3)"]Listen to our CMO discuss the hemophilia program[/spotlight-link] [spotlight-link icon="presentation" href=http://www.alnylam.com/web/assets/ALNY-Hemophilia-Program-Overview.pdf type="(1.5MB PPT)"]View the slides [/spotlight-link]

Our flagship effort from the Alnylam 5x15 strategy is our ALN-TTR program, which is currently enrolling patients in a Phase I study for the treatment of a disease called transthyretin-mediated amyloidosis (ATTR). [spotlight-link icon="release" href="http://investors.alnylam.com/releasedetail.cfm?ReleaseID=734394" type=" "]Read our press release[/spotlight-link] [spotlight-link icon="presentation" href="http://www.alnylam.com/web/assets/ALNY-PNS-Poster-ALN-TTR-NT-Study-June2011.pdf" type="(720KB PPT)"]ALNY-PNS-Poster-ALN-TTR-NT-Study-June2011[/spotlight-link] [spotlight-link icon="presentation" href="http://www.alnylam.com/web/assets/ALNY-PNS-Poster-ALN-TTR-June2011.pdf" type="(1.1MB PPT)"]ALNY-PNS-Poster-ALN-TTR-June2011[/spotlight-link] [spotlight-link icon="presentation" href="http://www.alnylam.com/web/Files/Roundtables/ALNY-RNAiRndTble-ALNTTR-100722.pdf" type="(1.0 MB PPT)"] ALN-TTR RNAi Roundtable, July 2010[/spotlight-link]

At the ASCO Annual Meeting in June 2011, we presented complete results from our Phase I clinical trial with ALN-VSP, a systemically delivered RNAi therapeutic for the treatment of patients with advanced solid tumors with liver involvement. [spotlight-link icon="release" href="http://investors.alnylam.com/releasedetail.cfm?ReleaseID=734381" type=" "]Read our press release[/spotlight-link] [spotlight-link icon="presentation" href="http://www.alnylam.com/web/assets/ALN-VSP-PhI-ClinicalStudyResults-ASCO2011.pdf" type="(1.2MB PPT)"]ALN-VSP PhI ClinicalStudyResults-ASCO2011[/spotlight-link] [spotlight-link icon="presentation" href="http://www.alnylam.com/web/Files/Roundtables/ALNY-RNAi_Roundtable_POM_May2011.pdf" type="(2.2 MB PPT)"] ALN-VSP RNAi Roundtable, May 2011[/spotlight-link] [spotlight-link icon="podcast" href="http://www.alnylam.com/web/assets/alnylam_podcast_VSP_PhIresults.mp3" type="(3.1MB MP3)"]Listen to Dr. Jared Gollob discuss ALN-VSP data at ASCO 2011[/spotlight-link]

In June 2011, our scientists presented an update on our Huntington’s disease program, ALN-HTT, at the 26th Annual HDSA National Convention. [spotlight-link icon="presentation" href="http://www.alnylam.com/web/assets/June2011-HDSA-ALNY-MDT-ALN-HTT-pres.pdf" type="(1.8MB PPT)"]HDSA 2011 Presentation[/spotlight-link]  

In January 2011, Jared Gollob, M.D., Senior Director of Clinical Research at Alnylam, presented important clinical data from our ALN-VSP Phase I trial, demonstrating that RNAi can be harnessed in man using systemically delivered RNAi therapeutics. [spotlight-link icon="release" href="http://investors.alnylam.com/releasedetail.cfm?ReleaseID=734453" type=""]Read our press release[/spotlight-link] [spotlight-link icon="podcast" href="http://www.alnylam.com/web/Files/Presentations/Alnylam-RNAiPOM-Jan2011.pdf" type=""]Dana Farber ALN-VSP Proof of Mechanism[/spotlight-link]

Alnylam scientists and collaborators presented new pre-clinical data from our ALN-TTR program at the XII International Symposium on Amyloidosis in Rome on April 18 - 21, 2010. These data demonstrated, for the first time, that treatment with an RNAi therapeutic can result in regression of...

SIGN UP FOR PATIENT CONNECT

Receive updates on our investigational therapies and clinical trials.